TMRW Life Sciences Stock
TMRW Life Sciences provides an integrated platform for automated, software-guided cryospecimen management.
Sign up today and learn more about TMRW Life Sciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About TMRW Life Sciences Stock
TMRW is a life sciences technology company setting new standards for transparency, safety, and accountability in IVF and cell management. TMRW's platform, the world's first automated cryo-management for eggs and embryos, provides a complete digital chain of custody fully integrated with a robotic storage and monitoring solution. This is in contrast to the manual and analog methods that have gone unchanged throughout the history of IVF. With TMRW's platform, clinics significantly reduce the chances of potentially devastating errors. The TMRW team includes celebrated innovators in fertility, embryology, cryo-management, automation, software development, and robotics. TMRW is founded by Joshua Abram, Alan Murray, and Dr. Jeffrey Port in 2018 and is based in New York, New York.
Funding History
| May 2019 | $12.0M |
|---|---|
| December 2019 | $36.5M |
| July 2021 | $105M |
Management
Founder & Co-CEO
Joshua Abram
Board Member
Emily Drabant Conley
Independent Director
Tara Comonte
Senior Vice President Of Sales
Brian E Miller
Founder & Chief Medical Officer
Jeffrey Port
Board Member
Andrew Schwab
Board Observer
Mira Chaurushiya
COO & CFO
Melanie Goldey
Executive Board Member, Advisory Board Member; Fertiliy Tech, Fashion, VC
Robbie Myers
Board Member
David Sable
Strategic Advisor
Ellen Lubman
Board Director
Robbie Myers
Founder & Co-CEO
Alan Murray
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
